129 related articles for article (PubMed ID: 36369599)
1. PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma-a case report.
Tamura M; Yokogami K; Watanabe T; Kawano T; Muta J; Yamashita S; Oguri N; Sato Y; Takeshima H
Brain Tumor Pathol; 2023 Jan; 40(1):40-44. PubMed ID: 36369599
[TBL] [Abstract][Full Text] [Related]
2. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
Campanini ML; Colli LM; Paixao BM; Cabral TP; Amaral FC; Machado HR; Neder LS; Saggioro F; Moreira AC; Antonini SR; de Castro M
Horm Cancer; 2010 Aug; 1(4):187-96. PubMed ID: 21761366
[TBL] [Abstract][Full Text] [Related]
3. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
[TBL] [Abstract][Full Text] [Related]
4. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
5. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Boorjian S
Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
[TBL] [Abstract][Full Text] [Related]
6. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
7. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
8. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
10. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
11. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
13. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
14. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
[TBL] [Abstract][Full Text] [Related]
15. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
[TBL] [Abstract][Full Text] [Related]
16. Modeling Renal Cell Carcinoma in Mice:
Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
[TBL] [Abstract][Full Text] [Related]
17. Craniopharyngioma involving the infrasellar region: a case report and review of the literature.
Fujimoto Y; Matsushita H; Velasco O; Rosemberg S; Plese JP; Marino R
Pediatr Neurosurg; 2002 Oct; 37(4):210-6. PubMed ID: 12372916
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
Apps JR; Martinez-Barbera JP
Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
[TBL] [Abstract][Full Text] [Related]
20. Malignant transformation of craniopharyngioma with detailed follow-up.
Wang W; Chen XD; Bai HM; Liao QL; Dai XJ; Peng DY; Cao HX
Neuropathology; 2015 Feb; 35(1):50-5. PubMed ID: 25112406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
